{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:45:23Z","timestamp":1792986323782,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.prro.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T08:01:13Z","timestamp":1653984073000},"page":"370-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline"],"prefix":"10.1016","volume":"12","author":[{"given":"Lia M.","family":"Halasz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-0501","authenticated-orcid":false,"given":"Lisa","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Brat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia N.","family":"Laack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisha","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Lebow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Niemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay A.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Nana","family":"Yeboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2022.05.004_bib0001","series-title":"Clinical Practice Guidelines We Can Trust","article-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"key":"10.1016\/j.prro.2022.05.004_bib0002","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","article-title":"Committee on Standards for Systematic Reviews of Comparative Effectiveness Research","year":"2011"},{"key":"10.1016\/j.prro.2022.05.004_bib0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.prro.2022.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0005","series-title":"World Health Organization Classification of Tumours of the Central Nervous System","article-title":"WHO Classification of Tumours Editorial Board","year":"2021"},{"key":"10.1016\/j.prro.2022.05.004_bib0006","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2022.05.004_bib0007","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2022.05.004_bib0008","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/neuonc\/nox132","article-title":"Prognostic relevance of genetic alterations in diffuse lower-grade gliomas","volume":"20","author":"Aoki","year":"2018","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.prro.2022.05.004_bib0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00401-015-1438-8","article-title":"IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: A grading problem for WHO","volume":"129","author":"Reuss","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.prro.2022.05.004_bib0011","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/jnen\/nlz082","article-title":"Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma","volume":"78","author":"Yoda","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.prro.2022.05.004_bib0012","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0013","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.radonc.2017.09.027","article-title":"Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas","volume":"125","author":"Yeboa","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0014","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jocn.2018.09.010","article-title":"Patterns of care and outcomes of postoperative radiation for low-grade gliomas in United States hospitals","volume":"58","author":"Youssef","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.prro.2022.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult glioma incidence and survival by race or ethnicity in the United States From 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cncr.21733","article-title":"Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001","volume":"106","author":"Claus","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2022.05.004_bib0017","first-page":"288","article-title":"Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: A population-based study","volume":"7","author":"Ryan","year":"2020","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.prro.2022.05.004_bib0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3171\/JNS\/2008\/109\/11\/0835","article-title":"Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial","volume":"109","author":"Shaw","year":"2008","journal-title":"J Neurosurg"},{"key":"10.1016\/j.prro.2022.05.004_bib0019","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0360-3016(01)02692-X","article-title":"Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: An interim analysis","volume":"52","author":"Karim","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0020","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","article-title":"Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802","volume":"30","author":"Shaw","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0021","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2022.05.004_bib0022","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0023","first-page":"249","article-title":"Management of low-grade glioma: A systematic review and meta-analysis","volume":"6","author":"Brown","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.prro.2022.05.004_bib0024","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2022.05.004_bib0025","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","volume":"24","author":"van den Bent","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0026","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0027","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2005.04.3414","article-title":"Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402","volume":"24","author":"Cairncross","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0028","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0029","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijrobp.2020.03.027","article-title":"Phase 2 study of a temozolomide-based chemoradiation therapy regimen for high-risk, low-grade gliomas: Long-term results of Radiation Therapy Oncology Group 0424","volume":"107","author":"Fisher","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0031","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: A phase 3, randomised, open-label intergroup study","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2022.05.004_bib0032","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-017-2443-7","article-title":"Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma","volume":"133","author":"Haque","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0033","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2003.04.172","article-title":"Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination","volume":"21","author":"Brown","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0034","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2004.11.011","article-title":"Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma","volume":"62","author":"Combs","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijrobp.2019.01.003","article-title":"Impact of radiation target volume on health-related quality of life in patients with low-grade glioma in the 2-year period post treatment: A secondary analysis of the EORTC 22033-26033","volume":"104","author":"Dirven","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0036","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","article-title":"A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844","volume":"36","author":"Karim","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0037","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2002.09.126","article-title":"Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group\/Radiation Therapy Oncology Group\/Eastern Cooperative Oncology Group study","volume":"20","author":"Shaw","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0038","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide","volume":"27","author":"Wick","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0039","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-019-03250-8","article-title":"Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas","volume":"144","author":"Fukuya","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","article-title":"Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: Preliminary results of Radiation Therapy Oncology Group 0424","volume":"91","author":"Fisher","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0041","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2022.05.004_bib0042","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","article-title":"CODEL: Phase III study of RT, RT\u202f+\u202fTMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design","volume":"23","author":"Jaeckle","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0043","first-page":"30","article-title":"Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma","volume":"9","author":"Bronk","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0044","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/cncr.32352","article-title":"Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma","volume":"125","author":"Back","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2022.05.004_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2018.01.099","article-title":"Association of 1p\/19q codeletion and radiation necrosis in adult cranial gliomas after proton or photon therapy","volume":"101","author":"Acharya","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0046","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7785\/tcrt.2012.500233","article-title":"Volumetric response evaluation after intensity modulated radiotherapy in patients with supratentorial gliomas","volume":"11","author":"Cho","year":"2012","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2022.05.004_bib0047","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/neuonc\/noaa021","article-title":"Final report from Intergroup NCCTG 86-72-51 (Alliance): A phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma","volume":"22","author":"Breen","year":"2020","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0048","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2019.04.027","article-title":"Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma","volume":"137","author":"Tabrizi","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0049","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/j.prro.2019.02.002","article-title":"Patterns of failure among patients with low-grade glioma treated with proton radiation therapy","volume":"9","author":"Kamran","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0050","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/cncr.29237","article-title":"Proton therapy for low-grade gliomas: Results from a prospective trial","volume":"121","author":"Shih","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2022.05.004_bib0051","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/0284186X.2018.1529424","article-title":"Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: Results of a multicentric in silico ROCOCO trial","volume":"58","author":"Eekers","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7785\/tcrt.2012.500276","article-title":"A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy","volume":"12","author":"Dennis","year":"2013","journal-title":"Technol Cancer Res Treat"},{"issue":"3 suppl","key":"10.1016\/j.prro.2022.05.004_bib0053","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ijrobp.2009.04.096","article-title":"Radiation therapy and hearing loss","volume":"76","author":"Bhandare","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2022.05.004_bib0054","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","article-title":"Radiation dose-volume effects in the spinal cord","volume":"76","author":"Kirkpatrick","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2022.05.004_bib0055","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","article-title":"Radiation dose-volume effects in the brain","volume":"76","author":"Lawrence","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2022.05.004_bib0056","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ijrobp.2009.07.1753","article-title":"Radiation dose-volume effects of optic nerves and chiasm","volume":"76","author":"Mayo","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2022.05.004_bib0057","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ijrobp.2009.08.078","article-title":"Radiation associated brainstem injury","volume":"76","author":"Mayo","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0058","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0959-8049(98)00268-8","article-title":"Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group","volume":"34","author":"Kiebert","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2022.05.004_bib0059","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1215\/15228517-2008-073","article-title":"Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131","volume":"11","author":"Vogelbaum","year":"2009","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0060","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0061","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-019-03297-7","article-title":"Oligodendroglioma confers higher risk of radiation necrosis","volume":"145","author":"Ahmad","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0062","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0360-3016(03)00533-9","article-title":"Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: A 10-year update of a phase II study","volume":"57","author":"Jeremic","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0063","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ijrobp.2009.06.004","article-title":"Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation Therapy Oncology Group trial 9402","volume":"77","author":"Wang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2022.05.004_bib0064","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: Long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.prro.2022.05.004_bib0065","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1200\/JCO.2007.12.7514","article-title":"Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: Results of a European Organisation for Research and Treatment of Cancer randomized clinical trial","volume":"25","author":"Taphoorn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0066","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S1470-2045(16)30305-9","article-title":"Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study","volume":"17","author":"Reijneveld","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2022.05.004_bib0067","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850022001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850022001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:24:21Z","timestamp":1761819861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850022001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1879850022001448"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2022.05.004","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}